Zhong Lun advised LaNova Medicines in Completing its CNY 300 Million Series C1 Financing and Entering into Strategic Collaboration with Sino Biopharm.LaNova Medicines Technology (Shanghai) Co.,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
